ESI Group and China Automotive Engineering Research Institute Co., Ltd. join forces on Intelligent Simulation
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241217795172/en/
ESI Group (Paris:ESI) and the China Automotive Engineering Research Institute Co. Ltd. (CAERI) have launched a partnership to advance intelligent simulation technology for the automotive industry. This collaboration, marked by the establishment of the Intelligent Simulation Center of Excellence in Chongqing (China), was celebrated with a ceremony attended by Jianwen Zhou, General Manager of the Testing Business Department at CAERI, Guojie Wang, Deputy Director of the Safety Center of the Testing Business Department at CAERI, Qingjiang Zhao, Deputy Director of the Safety Center of the Testing Business Department at CAERI, Corinne Romefort-Régnier, Senior Vice-President, General Secretary & Governance at ESI Group, and Kin-Choong Chan, General Manager at ESI Group’s Asia Pacific region.
The partnership will focus on co-developing cutting-edge virtual simulation solutions tailored to China’s evolving automotive sector while exploring international opportunities. By combining ESI Group’s global expertise and CAERI’s industry leadership, this initiative promises to enhance efficiency, safety, and sustainability across the automotive value chain.
“This partnership signifies a new chapter in automotive simulation,” said Corinne Romefort-Régnier, Senior Vice-President, General Secretary & Governance at ESI Group. “Together, we can deliver groundbreaking solutions that address the needs of the industry and support its transition toward a more sustainable future.”
Jianwen Zhou, General Manager of the Testing Business Department at CAERI, added: “This is a milestone collaboration that will contribute to the development of the automotive industry by leveraging the Center of Excellence for Intelligent Simulation to create innovative solutions in the field of intelligent simulation for customers in China and around the world.”
With the Intelligent Simulation Center of Excellence as its cornerstone, this partnership is set to accelerate innovation and strengthen the industry’s digital transformation on a global scale.
About ESI Group
ESI Group, a part of Keysight Technologies, provides reliable and customized solutions anchored on predictive physics modeling and virtual prototyping expertise. Acting principally in automotive, land transportation, aerospace and defense, and heavy industry, ESI software enables engineers to simulate mechanical designs, smart manufacturing processes, and human-centric workflows to make better decisions earlier in the product lifecycle. Keysight is an S&P 500 company delivering market-leading design, emulation, and test solutions to help engineers develop and deploy faster, with less risk, throughout the entire product lifecycle. For further information, go to: www.esi-group.com
Follow ESILinkedIn | Facebook | Twitter | YouTube
About CAERI
CAERI is subordinated to the China Certification and Inspection Group. As a central state-owned enterprise holding a listed company, it actively fulfills its responsibilities and has received accolades as a “Science and Technology Innovation Demonstrative Enterprise” and a “Benchmark Enterprise.” As a national-level research institute, CAERI is authorized by the Ministry of Industry and Information Technology, the Ministry of Ecology and Environment, the State Administration for Market Regulation, and the Ministry of Transport for automotive product announcements, environmental protection, China Compulsory Certification (CCC), and fuel consumption testing. It houses national-level platforms such as the National Gas Vehicle Engineering Research Center, the National Key Laboratory of Automotive Noise, Vibration, and Safety Technology, the National and Local Joint Engineering Laboratory for Alternative Fuel Vehicles, the National Intelligent Clean Energy Vehicle Quality Inspection and Testing Center, the National Robot Testing and Evaluation Center (Chongqing), the National Motor Vehicle Quality Inspection and Testing Center (Chongqing), the National Hydrogen Power Quality Inspection and Testing Center, and the National Motor Vehicle Quality Inspection and Testing Center (Guangdong). CAERI serves as a crucial base and technical support institution for product development, experimental research, and quality testing in China's automotive industry.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241217795172/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ImmunAbs Announces FDA Phase 2 IND Approval of IM-101, a Novel Complement C5 Inhibitor, for Treatment of Myasthenia Gravis2.6.2025 13:00:00 CEST | Press release
ImmunAbs Inc., a clinical-stage biotech specializing in developing antibody therapeutics, today announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) application to initiate a Phase 2 clinical trial evaluating the safety and efficacy of IM-101, a novel complement C5 inhibitor, for the treatment of Myasthenia Gravis. The forthcoming multicenter, randomized, double-blind, placebo-controlled study will enroll up to 90 patients to evaluate the effectiveness and safety of monthly IM-101 dosing in relieving complement-induced symptoms in MG. “This IND approval is pivotal for us as it brings us one step closer to delivering a transformative therapy for patients with autoimmune disorders”, said Dr. Dongjo Kim, the CEO of ImmunAbs, “we believe IM-101 has the potential to deliver deeper therapeutic responses and more durable remissions in patients who have failed to achieve sustained remission with current approved treatment.” About Myasthenia Gravis
Lenovo and Bellevue University Team Up to Offer Supply Chain and Logistics Education to Deliver “Smarter Technology for All”2.6.2025 13:00:00 CEST | Press release
Learners will have access to Lenovo’s globally recognized supply chain expertise through real-world case studies and subject matter experts. Lenovo, the global technology powerhouse, recognized in the top 10 in the Gartner Supply Chain Top 25, and Bellevue University, one of the nation’s top online universities, are teaming up to develop the next generation of supply chain professionals. “We believe that bringing real-world Global Supply Chain experience and learning directly into an education curriculum is precisely the optimal way to upskill the workforce of the future,” said Ben Massie, Vice President, Global Supply Chain, Lenovo. “Teaming up with Bellevue allows us to attract the right talent using the right technology and deliver on our mission to make ‘smarter technology for all’ a reality.” As a preferred higher education institution tapped to team up with Lenovo to offer supply chain short-term learning, Bellevue will leverage the breadth and depth of Lenovo’s supply chain expe
Lifezone Metals Files Initial Assessment for the Kabanga Nickel Project in Tanzania2.6.2025 12:30:00 CEST | Press release
Vertically Integrated Plan includes Hydrometallurgical Refinery at Kahama $2.37 Billion After-Tax NPV (8%) and 22.9% After-Tax IRR at $8.49 per Pound Nickel Price Initial Assessment Proposes a 22-Year Mine Plan at Average 2.39% Nickel Equivalent Grade Webcast with Technical Leadership Team at 10 AM ET on Tuesday, June 3, 2025 Lifezone Metals Limited’s (NYSE: LZM) Chief Executive Officer, Chris Showalter, and Chief Operating Officer, Gerick Mouton, announce today the results from the Initial Assessment for its flagship Kabanga Nickel Project in northwest Tanzania. The Initial Assessment evaluates a vertically integrated mining, processing and refining operation, commencing with a high-grade nickel sulfide underground mine and concentrator at the Kabanga site, followed five years later by a hydrometallurgical refinery at Kahama. The study covers the Main, MNB, Kima, North, and Tembo zones and is based on the December 2024 Mineral Resource Update (refer to Lifezone’s December 5, 2024 news
Corpay Cross-Border Named an Official Partner of Real Madrid C.F.2.6.2025 12:00:00 CEST | Press release
Providing access to currency risk management and cross-border payments solutions Corpay, Inc.*, (NYSE: CPAY) a global leader in corporate payments, is pleased to announce that Corpay’s Cross-Border business has entered into an agreement with Real Madrid C.F. to become an Official Partner. Through this partnership, Real Madrid will be able to gain access to and utilise Corpay Cross Border’s innovative solutions to help mitigate foreign exchange exposure from their day-to-day business needs. "The Corpay Cross-Border team is elated to be named an Official Partner of Real Madrid, one of the world’s most widely recognized and followed sports franchises," said Brad Loder, Chief Marketing Officer, Corpay Cross-Border Solutions. “With our strong focus on growing the Corpay brand, as well as our currency risk management business, we are excited to partner with one of the most successful football clubs in the world.” About Corpay Corpay, Inc. (NYSE: CPAY) is a global S&P500 corporate payments co
BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 20252.6.2025 12:00:00 CEST | Press release
Preliminary results highlight anti-tumor activity and favorable safety profiles of both B7-H4-targeting ADC and CDK2 inhibitorData underscore strength of emerging breast cancer pipeline as part of BeOne’s global transformation with next wave of innovation BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, announced new clinical data from its emerging breast cancer pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Poster presentations feature preliminary results of the dose escalation studies of two investigational molecules: BG-C9074, a novel B7-H4-targeting antibody-drug conjugate (ADC) in patients with advanced solid tumors, including breast cancer, and BG-68501, a cyclin-dependent kinase-2 inhibitor (CDK2i), in HR+/HER2- breast cancer patients with prior CDK4/6i exposure. “Presenting the first clinical data for two novel breast cancer candidates at ASCO 2025 marks a pivotal moment for BeOne,” said Mark Lanas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom